

Justin M Watts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12127445/publications.pdf>

Version: 2024-02-01

21
papers

589
citations

933447

10
h-index

888059

17
g-index

22
all docs

22
docs citations

22
times ranked

1180
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 1893-1903.	7.0	23
2	Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development. <i>Cancers</i> , 2020, 12, 3225.	3.7	52
3	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <i>Blood</i> , 2020, 135, 463-471.	1.4	266
4	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 231-231.	1.4	23
5	Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. <i>Leukemia Research</i> , 2018, 64, 34-41.	0.8	41
6	Leveraging Hypomethylating Agents for Better MDS Therapy. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 507-515.	2.3	0
7	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3819-3825.	8.2	45
8	Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 688-688.	1.4	8
9	A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1492.	4.1	10
10	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. <i>Blood</i> , 2017, 130, 794-794.	1.4	0
11	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. <i>Leukemia Research</i> , 2016, 50, 123-131.	0.8	50
12	Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 49, 62-65.	0.8	17
13	Early Detection of Myelodysplastic Syndromes: Maximizing the Utility of Automated Hematology. <i>Blood</i> , 2016, 128, 5527-5527.	1.4	1
14	Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. <i>British Journal of Haematology</i> , 2015, 171, 84-90.	2.5	14
15	Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: a case series with molecular genetic analysis and review of the literature. <i>Leukemia and Lymphoma</i> , 2014, 55, 2125-2129.	1.3	15
16	Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. <i>Leukemia Research</i> , 2014, 38, 901-906.	0.8	10
17	Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?. <i>Blood</i> , 2014, 124, 1004-1004.	1.4	4
18	Telomere Length Is Associated with Specific Mutations and Mutation Classes in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2280-2280.	1.4	8

#	ARTICLE	IF	CITATIONS
19	Sodium Salicylate Has a Priming Effect When Combined with Azacitidine in Pre-Clinical Models of AML. Blood, 2014, 124, 2300-2300.	1.4	0
20	Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 5274-5274.	1.4	0
21	Treatment breakthroughs for the management of acute myeloid leukemia. International Journal of Hematologic Oncology, 2012, 1, 121-132.	1.6	0